Lung Cancer Issues. Learn about the symptoms, detection and treatment of  Lung Cancer.
A Member of the Healthscout Network
 Printer Friendly  Send to a Friend

Coming Soon: Lung-Cancer Spray?

Novel delivery of gene therapy suppresses tumors in mice

MONDAY, June 15 (HealthDay News) -- Scientists may someday be able to fight lung cancer using gene therapy delivered by an inhalable spray.

In a new study, mice with lung cancer that were treated with a vaporized viral vector twice a week for four weeks had fewer, smaller tumors than untreated mice.

Advertisement
Related Stories
 border=
FDA Advisers Say Avastin Shouldn't Be Used for Breast Cancer
U.S. Cancer Death Rate Keeps Falling: Report
Tailored Treatment for Advanced Lung Cancer?
Related Videos
 border=
Detecting Lung Disease
Targeting Lung Cancer
Saving Lungs
Related Slides
 border=
Lung Cancer


Researchers also found that treated mice had increased apoptosis, or programmed cell death, necessary for healthy tissues, as well as suppressed production of several proteins that contribute to cancer cell growth.

The study, by researchers at Seoul National University in Korea, appears in the June 15 issue of the American Journal of Respiratory and Critical Care Medicine.

"Aerosol delivery targets the lungs specifically and represents a noninvasive alternative for targeting genes to the lung," wrote study author Myung-Haing Cho, a professor at Seoul National University. "The delivery of genes via aerosol holds promise for the treatment of a broad spectrum of pulmonary disorders and offers numerous advantages over more invasive modes of delivery."

In the study, researchers used a lentiviral vector derived from a retrovirus able to infect non-dividing cells, causing lasting genetic changes. The lentiviral vector included a carboxyl-terminal modulator protein (CTMP), which inhibits Akt signaling.

Previous research has shown 90 percent of non-small cell lung carcinomas involve the Akt signaling pathway, according to the study.

Researchers divided mice into three groups: one received the aerosolized CTMP vector, one received the vector alone and one third were untreated.

The mice treated by the CTMP vector had significantly fewer, smaller tumors.

Globally, lung cancer is the most common cause of cancer deaths. Most treatments, including surgery, radiation and chemotherapy, slow progression of the disease only temporarily.

While much research is underway on the use of gene therapy to treat lung cancer, one stumbling block has been finding delivery mechanisms that work.

"Our results demonstrated that lentivirus-mediated CTMP overexpression suppressed Akt activity and inhibited tumor progression," Cho wrote.

More information

The National Cancer Institute has more on lung cancer.

-- Jennifer Thomas

SOURCE: American Journal of Respiratory and Critical Care Medicine, news release, June 15, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/15/2009



Disclaimer: The information provided on this website is for educational purposes only and does not serve as a replacement for care provided by your own personal health care team. This website does not render or provide medical advice, and no individual should make any medical decisions or change their health behavior based on information provided here. All pertinent content provided on this website should be discussed with your personal physician to evaluate whether it has any relevance to or impact on your specific condition. Reliance on any information provided by this website is solely at your own risk.


Jul 29, 2010
Home
Search
Powered By HealthLine
Patient Guide
News
Health Videos
Health Encyclopedia
Health News Archive
Affiliate Information
HealthScout Network
Contact Us
Newsletters
Privacy Policy
Terms of Use

We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service  

To find more information on specific conditions, please visit our partner sites: